30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Metagenomi Inc (MGX)

Track

Over the last 90 days, Metagenomi Inc. has seen net insider selling totaling $3,746.32. This activity is primarily driven by sales from executives, including the Chief Financial Officer and CEO. There were no insider purchases recorded during this period. The stock has experienced a 9.1% price decrease over the past 90 days.
Stock chart
Ticker: MGX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Irish Jian
See Remarks
1 sale — total 100,000 USD
Planned sale 5 Jun 2026
Value US$4,542,070.17 | Price 147.34 | Shares 15,186
Planned sale 5 Jun 2026
Value US$1,450,089.03 | Price 271.46 | Shares 59,013
Sale 5 Jun 2026
Value US$100,000.00 | Price 1.30 | Shares 1,000
Sale 5 Mar 2026
Value US$2,529.60 | Price 1.60 | Shares 1,581
Sale 5 Mar 2026
Value US$2,571.20 | Price 1.60 | Shares 1,607
Sale 5 Mar 2026
Value US$771.20 | Price 1.60 | Shares 482
Sale 5 Dec 2025
Value US$6,786.38 | Price 1.77 | Shares 3,830
Sale 5 Dec 2025
Value US$2,792.51 | Price 1.77 | Shares 1,576
Sale 5 Dec 2025
Value US$2,838.58 | Price 1.77 | Shares 1,602
Sale 5 Dec 2025
Value US$352.61 | Price 1.77 | Shares 199
Proposed sale 11 Sep 2025
Value US$68,080.80 | Price 1.90 | Shares 35,832
Sale 5 Sep 2025
Value US$4,888.81 | Price 1.81 | Shares 2,701
Planned sale 5 Sep 2025
Value US$2,899.62 | Price 1.81 | Shares 1,602
Sale 5 Sep 2025
Value US$2,852.56 | Price 1.81 | Shares 1,576
Planned sale 5 Sep 2025
Value US$360.19 | Price 1.81 | Shares 199
Proposed sale 9 Jul 2025
Value US$1,470,404.00 | Price 1.91 | Shares 769,845
Sale 6 Jun 2025
Value US$348.25 | Price 1.75 | Shares 199
Sale 6 Jun 2025
Value US$18,873.75 | Price 1.75 | Shares 10,785
Sale 6 Jun 2025
Value US$9,168.25 | Price 1.75 | Shares 5,239
Sale 6 Jun 2025
Value US$2,758.00 | Price 1.75 | Shares 1,576
Sale 6 Jun 2025
Value US$11,182.50 | Price 1.75 | Shares 6,390
Sale 5 Mar 2025
Value US$1,743.56 | Price 1.87 | Shares 930
Sale 5 Mar 2025
Value US$3,389.64 | Price 1.87 | Shares 1,808
Sale 5 Dec 2024
Value US$2,899.74 | Price 1.86 | Shares 1,559
Sale 5 Sep 2024
Value US$18,043.20 | Price 2.88 | Shares 6,265
Buy 13 Feb 2024
Value US$12,000,000.00 | Price 15.00 | Shares 800,000
Buy 9 Feb 2024
Value US$1,025,000.00 | Price 10.25 | Shares 100,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-05 PlS Planned sale
2.6
Irish Jian

See Remarks

Executive Director
15,186 -4.7%
147.34
US$4,542,070 		15,186 -4.7% 147.34 US$4,542,070
2026-06-10 2026-06-05 PlS Planned sale
3.6
Wein Matthew

See Remarks

Officer
59,013 +31.7%
271.46
US$1,450,089 		59,013 +31.7% 271.46 US$1,450,089
2026-06-10 2026-06-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
92,315 +28.4%
416.12
US$2,658,509 		92,315 +28.4% 416.12 US$2,658,509
2026-03-09 2026-03-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,581 -0.8%
1.60
US$2,530 		1,581 -0.8% 1.60 US$2,530
2026-03-09 2026-03-05 S Sale
2.6
Irish Jian

Chief Executive Officer

Executive Director
1,607 -0.5%
1.60
US$2,571 		1,607 -0.5% 1.60 US$2,571
2026-03-09 2026-03-05 S Sale
3.6
Wein Matthew

See Remarks

Officer
482 -0.4%
1.60
US$771 		482 -0.4% 1.60 US$771
2025-12-08 2025-12-05 S Sale
2.3
Thomas Brian C.
Non-Executive Director
3,830 -0.2%
1.77
US$6,786 		3,830 -0.2% 1.77 US$6,786
2025-12-08 2025-12-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -0.8%
1.77
US$2,793 		1,576 -0.8% 1.77 US$2,793
2025-12-08 2025-12-05 S Sale
2.6
Irish Jian

Chief Executive Officer

Executive Director
1,602 -0.3%
1.77
US$2,839 		1,602 -0.3% 1.77 US$2,839
2025-12-08 2025-12-05 S Sale
3.6
Wein Matthew

See Remarks

Officer
199 -0.2%
1.77
US$353 		199 -0.2% 1.77 US$353
2025-09-11 2025-09-11 PrS Proposed sale
1.5
Noonberg Sarah B.

FORMER OFFICER

Officer
35,832
1.90
US$68,081 		35,832 1.90 US$68,081
2025-12-01 2025-09-05 S Sale
2.3
Thomas Brian C.
Non-Executive Director
2,701 -0.1%
1.81
US$4,889 		2,701 -0.1% 1.81 US$4,889
2025-12-01 2025-09-05 PlS Planned sale
2.6
Irish Jian

Chief Executive Officer

Executive Director
1,602 -0.5%
1.81
US$2,900 		1,602 -0.5% 1.81 US$2,900
2025-12-01 2025-09-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -2.2%
1.81
US$2,853 		1,576 -2.2% 1.81 US$2,853
2025-12-01 2025-09-05 PlS Planned sale
3.6
Wein Matthew

See Remarks

Officer
199 -1.0%
1.81
US$360 		199 -1.0% 1.81 US$360
2025-07-09 2025-07-09 PrS Proposed sale
Sebastian Bernales

Affiliate
769,845
1.91
US$1,470,404 		769,845 1.91 US$1,470,404
2025-06-09 2025-06-06 S Sale
3.6
Wein Matthew

See Remarks

Officer
199 -1.2%
1.75
US$348 		199 -1.2% 1.75 US$348
2025-06-09 2025-06-06 S Sale
2.3
Thomas Brian C.

Chief Executive Officer

Executive Director
10,785 -0.4%
1.75
US$18,874 		10,785 -0.4% 1.75 US$18,874
2025-06-09 2025-06-06 S Sale
1.5
Noonberg Sarah B.

Chief Medical Officer

Officer
5,239 -4.6%
1.75
US$9,168 		5,239 -4.6% 1.75 US$9,168
2025-06-09 2025-06-06 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,576 -2.1%
1.75
US$2,758 		1,576 -2.1% 1.75 US$2,758
2025-06-09 2025-06-06 S Sale
2.6
Irish Jian

See Remarks

Executive Director
6,390 -2.0%
1.75
US$11,182 		6,390 -2.0% 1.75 US$11,182
2025-03-07 2025-03-05 S Sale
3.6
Wein Matthew

See Remarks

Officer
930 -8.9%
1.87
US$1,744 		930 -8.9% 1.87 US$1,744
2025-03-07 2025-03-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,808 -2.9%
1.87
US$3,390 		1,808 -2.9% 1.87 US$3,390
2024-12-06 2024-12-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
1,559 -2.5%
1.86
US$2,900 		1,559 -2.5% 1.86 US$2,900
2024-09-06 2024-09-05 S Sale
3.4
Wapnick Pamela

Chief Financial Officer

Officer
6,265 -9.0%
2.88
US$18,043 		6,265 -9.0% 2.88 US$18,043
2024-02-15 2024-02-13 B Purchase
2.3
Novo Holdings A/S
Large shareholder
800,000 +85.2%
15.00
US$12,000,000 		800,000 +85.2% 15.00 US$12,000,000
2024-02-15 2024-02-09 B Purchase
2.3
Novo Holdings A/S
Large shareholder
100,000 +inf%
10.25
US$1,025,000 		100,000 +inf% 10.25 US$1,025,000
Explore more

More insider trading research around Metagenomi Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America